SCHEMBL9542867

SCHEMBL9542867

CN1C(=O)Nc2ccc(Cl)cc2C1(CCCO)C1CC1

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 4/20 0.45
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
IDO1 P14902 2/20 0.39
HTR7 P34969 6/20 0.39
ELOVL6 Q9H5J4 1/20 0.36
CYP46A1 Q9Y6A2 1/20 0.35
MDM2 Q00987 1/20 0.35
PDE7A Q13946 1/20 0.34
USP2 O75604 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9539063 0.93 AKR1B1 (0.47) AKR1B1MEN1KMT2AIDO1HTR7
SCHEMBL9539079 0.86 AKR1B1 (0.48) AKR1B1MEN1KMT2AIDO1HTR7
SCHEMBL9539065 0.83 AKR1B1 (0.45) AKR1B1MEN1KMT2AIDO1HTR7
SCHEMBL9539064 0.82 IDO1 (0.54) AKR1B1MEN1KMT2AIDO1ELOVL6
SCHEMBL9539021 0.81 AKR1B1 (0.48) AKR1B1MEN1KMT2AIDO1HTR7
SCHEMBL9539125 0.81 AKR1B1 (0.47) AKR1B1MEN1KMT2AIDO1HTR7
SCHEMBL9539957 0.81 AKR1B1 (0.47) AKR1B1MEN1KMT2AIDO1HTR7
SCHEMBL9538999 0.80 AKR1B1 (0.49) AKR1B1MEN1KMT2AIDO1HTR7
SCHEMBL9541592 0.79 AKR1B1 (0.45) AKR1B1MEN1KMT2AIDO1HTR7
SCHEMBL9539967 0.76 AKR1B1 (0.43) AKR1B1MEN1KMT2AIDO1HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0530994-A1 Quinazoline derivatives as inhibitors of HIV reverse transcriptase MERCK & CO. INC. (US) 1993-03-10 EP disclosed
WO-1993004047-A1 QUINAZOLINE DERIVATIVES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE MERCK & CO., INC. (US) 1993-03-04 WO disclosed